I wrote a story last month about Genentech, Inc., a biotech giant with a huge plant in Oceanside, being bought out by Swiss drug maker Roche.

Today, despite market turmoil, Roche assured the Wall Street Journal that it’s still on track to offer the $43.7 billion bid to acquire all of the outstanding shares of Genentech.

A spokesperson for Roche declined to tell the Journal if the company plans to bid more than the $89 per share already on the table. Genentech had rejected the offer as too low, but kept the door wide open to a higher bid.

But investors seem skittish. After bidding Genentech shares up to $98, the stock price slipped to $86.50 yesterday afternoon.


Leave a comment

We expect all commenters to be constructive and civil. We reserve the right to delete comments without explanation. You are welcome to flag comments to us. You are welcome to submit an opinion piece for our editors to review.

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.